November 9, 2005 – According to D-Pharm of Rehovot, Israel, the clinical trial monitoring board recommended continuation of its Phase IIb trial for DP-b99 to treat acute stroke. DP-b99 is a neuroprotective substance that is administered intravenously for 4 days with a first administration up to 9 hours after the onset of stroke. The potential market for a successful stroke drug with an acceptable time window is huge. We look at stroke, this drug candidate, and D-Pharm...
